Long-term denosumab therapy safe for patients with breast, prostate cancer
the ONA take:
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
In the initial blinded phase 3 studies, patients with metastatic breast or prostate cancer received subcutaenous denosumab 120 mg every 4 weeks or intravenous zolendronic acid 4 mg every 4 weeks.
Denosumab was found to be superior in efficacy to zoledronic acid, and therefore patients could opt to participate in an open-label extension to receive long-term denosumab for up to an additional 2 years.
Researchers analyzed the data from the open-label extension to evaluate the safety results of extended denosumab therapy.
Results showed no new safety signals among patients who continued denosumab or among patients who switched from zoledronic acid to denosumab. Osteonecrosis of the jaw rates increased with increasing exposure to denosumab, while hypocalcemia rates were similar between the blinded treatment and open-label extension phases.
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|